参考文献/References:
[1] Dichgans M, Leys D. Vascular cognitive impairment[J]. Circ Res, 2017, 120(3):573-591.
[2] Wolters FJ, Ikram MA. Epidemiology of vascular dementia[J]. Arterioscler Thromb Vasc Biol, 2019, 39(8):1542-1549.
[3] Iadecola C, Duering M, Hachinski V, et al. Vascular cognitive impairment and dementia: JACC scientific expert panel[J]. J Am Coll Cardiol, 2019, 73(25):3326-3344.
[4] Rajeev V, Fann DY, Dinh QN, et al. Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment[J]. Theranostics, 2022, 12(4):1639-1658.
[5] Salvadores N, Searcy JL, Holland PR, et al. Chronic cerebral hypoperfusion alters amyloid-β peptide pools leading to cerebral amyloid angiopathy, microinfarcts and haemorrhages in Tg-SwDI mice[J]. Clin Sci (Lond), 2017, 131(16):2109-2123.
[6] 〖JP2〗Duncombe J, Kitamura A, Hase Y, et al. Chronic cerebral hypoperfusion: a key mechanism leading to vascular cognitive impairment and dementia. Closing the translational gap between rodent models and human vascular cognitive impairment and dementia[J]. Clin Sci (Lond), 2017, 131(19):2451-2468. 〖JP〗
[7] Choi BR, Lee SR, Han JS, et al. Synergistic memory impairment through the interaction of chronic cerebral hypoperfusion and amlyloid toxicity in a rat model[J]. Stroke, 2011, 42(9):2595-2604.
[8] Ayman, ElAli, Peter, et al. Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation[J]. Acta Neuropathol Commun, 2013, 1(1):75.
[9] Cortes-Canteli M, Zamolodchikov D, Ahn HJ, et al. Fibrinogen and altered hemostasis in Alzheimer’s disease[J]. J Alzheimers Dis, 2012, 32(3):599-608. 〖ZK）〗
[10]Zhao Y, Gu JH, Dai CL, et al. Chronic cerebral hypoperfusion causes decrease of O-GlcNAcylation, hyperphosphorylation of tau and behavioral deficits in mice[J]. Front Aging Neurosci, 2014, 6:10.
[11]Ahn HJ, Zamolodchikov D, Cortes-Canteli M, et al. Alzheimer’s disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization[J]. Proc Natl Acad Sci USA, 2010, 107(50):21812-21817.
[12]Vkuhlmann MT, Cuhlmann S, Hoppe I, et al. Implantation of a carotid cuff for triggering shear-stress induced atherosclerosis in mice[J]. J Vis Exp, 2012(59):3308.
[13]Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction[J]. Nat Med, 2019, 25(2):270-276.
[14]Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders[J]. Nat Rev Neurol, 2018, 14(3):133-150.
[15]Wang YP, Mandelkow E. Tau in physiology and pathology[J]. Nat Rev Neurosci, 2016, 17(1):5-21.
[16]〖JP3〗Goedert M.Neurodegeneration.Alzheimer’s and Parkinson’s diseases:the prion concept in relation to assembled Aβ,tau,and α-synuclein[J].Science,2015,349(6248):1255555.〖JP〗
[17]Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases[J]. Nature, 2013, 501(7465):45-51.
[18]Kell DB, Pretorius E. To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin?[J]. Semin Thromb Hemost, 2018, 44(3):224-238.
[19]Liu YT, Chen HJ, Kai Z, et al. High levels of plasma fibrinogen are related to post-stroke cognitive impairment[J]. Brain Behav, 2019, 9(10):e01391.
[20]〖JP2〗Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer’s disease[J]. J Exp Med, 2007, 204(8):1999-2008. 〖JP〗
[21]Bian ZH, Yamashita T, Shi XW, et al. Accelerated accumulation of fibrinogen peptide chains with Aβ deposition in Alzheimer’s disease (AD) mice and human AD brains[J]. Brain Res, 2021, 1767:147569.